Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
8.30
-0.19 (-2.24%)
Aug 29, 2025, 4:00 PM - Market closed
Aardvark Therapeutics Analyst Ratings
Total Analysts
5
Consensus Rating
Strong Buy
Price Target
$32.60
Upside
+292.77%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $26 → $25 | Strong Buy | Maintains | $26 → $25 | +201.20% | Aug 28, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $20 → $19 | Buy | Maintains | $20 → $19 | +128.92% | Aug 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +381.93% | Jun 30, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $21 → $20 | Buy | Maintains | $21 → $20 | +140.96% | May 15, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $21 | Buy | Reiterates | $21 | +153.01% | Apr 1, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $50 | Buy | Reiterates | $50 | +502.41% | Apr 1, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $22 → $26 | Strong Buy | Maintains | $22 → $26 | +213.25% | Mar 27, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $21 | Buy | Initiates | $21 | +153.01% | Mar 10, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $50 | Buy | Initiates | $50 | +502.41% | Mar 10, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $29 | Buy | Initiates | $29 | +249.40% | Mar 10, 2025 |
| B of A Securities | B of A Securities | Strong Buy Initiates $22 | Strong Buy | Initiates | $22 | +165.06% | Mar 10, 2025 |